$CHRS
Coherus BioSciences Inc Stock $chrs

$chrs Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000155837024003436 Filed on March 15, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$77.06M	$91.52M	$257.2M
YoY Change	137.58%	101.81%	21.89%
Cost Of Revenue	$34.59M	$84.57M	$159.0M
YoY Change	104.97%	495.46%	126.86%
Gross Profit	$42.48M	$6.957M	$98.25M
YoY Change	172.95%	-77.67%	-30.3%
Gross Profit Margin	55.12%	7.6%	38.19%
Selling, General & Admin	$56.53M	$49.49M	$192.0M
YoY Change	15.01%	-7.7%	-3.26%
% of Gross Profit	133.09%	711.43%	195.43%
Research & Development	$28.47M	$26.37M	$109.4M
YoY Change	-16.64%	-9.14%	-45.11%
% of Gross Profit	67.02%	379.01%	111.38%
Depreciation & Amortization	$600.0K	$1.091M	$3.200M
YoY Change	-36.78%	3.9%	-13.49%
% of Gross Profit	1.41%	15.68%	3.26%
Operating Expenses	$85.00M	$75.86M	$301.5M
YoY Change	2.03%	-8.21%	-24.23%
Operating Profit	-$42.53M	-$68.91M	-$203.2M
YoY Change	-37.23%	33.81%	-20.9%
Interest Expense	$11.12M	-$10.62M	-$40.54M
YoY Change	14.46%	13.15%	-224.84%
% of Operating Profit
Other Income/Expense, Net	$2.869M	-$129.0K	$5.469M
YoY Change	66.03%	-106.42%	43.09%
Pretax Income	$102.9M	-$79.65M	-$238.3M
YoY Change	-235.85%	35.3%	-18.33%
Income Tax	$0.00	$0.00	-$380.0K
% Of Pretax Income	0.0%
Net Earnings	$102.9M	-$79.65M	-$237.9M
YoY Change	-235.85%	35.3%	-18.46%
Net Earnings / Revenue	133.49%	-87.03%	-92.48%
Basic Earnings Per Share	$0.91		-$2.53
Diluted Earnings Per Share	$0.83	-$0.71	-$2.53
COMMON SHARES
Basic Shares Outstanding	112.7M	111.4M	94.16M
Diluted Shares Outstanding	125.5M		94.16M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$259.8M	$117.7M	$117.7M
YoY Change	102.81%	-38.57%	-38.57%
Cash & Equivalents	$259.8M	$102.9M	$102.9M
Short-Term Investments	$0.00	$14.86M	$14.86M
Other Short-Term Assets	$21.58M	$34.76M	$34.76M
YoY Change	-41.64%	-14.81%	-14.81%
Inventory	$61.98M	$130.1M	$130.1M
Prepaid Expenses
Receivables	$252.0M	$260.5M	$260.5M
Other Receivables	$32.19M	$0.00	$0.00
Total Short-Term Assets	$627.5M	$508.4M	$508.4M
YoY Change	98.62%	33.35%	33.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.188M	$5.119M	$11.03M
YoY Change	-45.78%	-41.52%	-23.63%
Goodwill		$943.0K
YoY Change		4.78%
Intangibles		$71.67M
YoY Change		1108.45%
Long-Term Investments
YoY Change
Other Assets	$9.131M	$49.56M	$49.56M
YoY Change	16.69%	471.77%	-37.45%
Total Long-Term Assets	$136.1M	$121.2M	$121.2M
YoY Change	57.3%	21.7%	21.7%
TOTAL ASSETS
Total Short-Term Assets	$627.5M	$508.4M	$508.4M
Total Long-Term Assets	$136.1M	$121.2M	$121.2M
Total Assets	$763.5M	$629.6M	$629.6M
YoY Change	89.74%	30.94%	30.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$38.29M	$35.22M	$35.22M
YoY Change	64.82%	205.56%	205.56%
Accrued Expenses	$115.7M	$169.6M	$169.6M
YoY Change	260.94%	238.63%	34.66%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$175.0M	$721.0K	$721.0K
YoY Change		-39.46%	-39.46%
Total Short-Term Liabilities	$538.3M	$169.6M	$169.6M
YoY Change	336.2%	22.32%	22.32%
LONG-TERM LIABILITIES
Long-Term Debt	$299.7M	$473.4M	$473.4M
YoY Change	-36.46%	0.19%	0.19%
Other Long-Term Liabilities	$2.734M	$180.0M	$180.0M
YoY Change	2580.39%	5092.24%	2437.21%
Total Long-Term Liabilities	$2.734M	$653.4M	$653.4M
YoY Change	2580.39%	18745.8%	36.24%
TOTAL LIABILITIES
Total Short-Term Liabilities	$538.3M	$169.6M	$169.6M
Total Long-Term Liabilities	$2.734M	$653.4M	$653.4M
Total Liabilities	$845.4M	$823.0M	$823.0M
YoY Change	41.15%	33.12%	33.12%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.477B	-$1.580B
YoY Change	4.18%	17.73%
Common Stock	$11.00K	$11.00K
YoY Change	37.5%	37.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$81.84M	-$193.4M	-$193.4M
YoY Change
Total Liabilities & Shareholders Equity	$763.5M	$629.6M	$629.6M
YoY Change	89.74%	30.94%	30.94%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$102.9M	-$79.65M	-$237.9M
YoY Change	-235.85%	35.3%	-18.46%
Depreciation, Depletion And Amortization	$600.0K	$1.091M	$3.200M
YoY Change	-36.78%	3.9%	-13.49%
Cash From Operating Activities	-$46.77M	-$12.94M	-$174.9M
YoY Change	-31.96%	-87.06%	-27.47%
INVESTING ACTIVITIES
Capital Expenditures		-$14.00K	$286.0K
YoY Change		-116.09%	-85.97%
Acquisitions
YoY Change
Other Investing Activities	-$52.00K	$34.95M	$144.6M
YoY Change	-100.29%	-126.92%	-187.76%
Cash From Investing Activities	$202.8M	$35.20M	$144.6M
YoY Change	1056.93%	-127.1%	-186.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$74.22M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	887.0K	366.0K	69.60M
YoY Change	-76.68%	-94.45%	28.12%
NET CHANGE
Cash From Operating Activities	-46.77M	-12.94M	-174.9M
Cash From Investing Activities	202.8M	35.20M	144.6M
Cash From Financing Activities	887.0K	366.0K	69.60M
Net Change In Cash	156.9M	22.63M	39.36M
YoY Change	-430.96%	-110.14%	-111.13%
FREE CASH FLOW
Cash From Operating Activities	-$46.77M	-$12.94M	-$174.9M
Capital Expenditures		-$14.00K	$286.0K
Free Cash Flow		-$12.92M	-$175.2M
YoY Change		-87.08%	-27.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.coherus.com/20231231#OperatingAndFinanceLeaseLiabilityNoncurrent
CY2023Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001512762
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	78851516
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	112215260
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	0
CY2023Q4	us-gaap	Property Plant And Equipment Useful Life Description Of Term Extensible Enumeration PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration	http://fasb.org/us-gaap/2023#UsefulLifeTermOfLeaseMember
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.coherus.com/20231231#OperatingAndFinanceLeaseLiabilityNoncurrent
CY2022Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36721
CY2023	dei	Entity Registrant Name EntityRegistrantName	Coherus BioSciences, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-3615821
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	333 Twin Dolphin Drive
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 600
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94065
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94065
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94065
CY2023	dei	City Area Code CityAreaCode	650
CY2023	dei	Local Phone Number LocalPhoneNumber	649-3530
CY2023	dei	Local Phone Number LocalPhoneNumber	649-3530
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	CHRS
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	324137955
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	112714488
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	San Mateo, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102891000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63547000
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	14857000
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	128134000
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	260522000
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	109964000
CY2023Q4	us-gaap	Inventory Net InventoryNet	62605000
CY2022Q4	us-gaap	Inventory Net InventoryNet	38791000
CY2023Q4	chrs	Prepaid Manufacturing Expense Current PrepaidManufacturingExpenseCurrent	23657000
CY2022Q4	chrs	Prepaid Manufacturing Expense Current PrepaidManufacturingExpenseCurrent	17880000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11099000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	22918000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	475631000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	381234000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5119000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8754000
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	67495000
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	76260000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	71673000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5931000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9686000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8668000
CY2023Q4	us-gaap	Assets Assets	629604000
CY2022Q4	us-gaap	Assets Assets	480847000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	35219000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11526000
CY2023Q4	chrs	Accrued Rebates Fees And Reserve Current AccruedRebatesFeesAndReserveCurrent	169645000
CY2022Q4	chrs	Accrued Rebates Fees And Reserve Current AccruedRebatesFeesAndReserveCurrent	54461000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	21521000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22610000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	105386000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	50097000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	331771000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	138694000
CY2023Q4	chrs	Term Loans Payable Noncurrent TermLoansPayableNoncurrent	246481000
CY2022Q4	chrs	Term Loans Payable Noncurrent TermLoansPayableNoncurrent	245483000
CY2023Q4	us-gaap	Convertible Subordinated Debt Noncurrent ConvertibleSubordinatedDebtNoncurrent	226888000
CY2022Q4	us-gaap	Convertible Subordinated Debt Noncurrent ConvertibleSubordinatedDebtNoncurrent	225575000
CY2023Q4	chrs	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	5328000
CY2022Q4	chrs	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	5046000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12561000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3467000
CY2023Q4	us-gaap	Liabilities Liabilities	823029000
CY2022Q4	us-gaap	Liabilities Liabilities	618265000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	112215260
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	78851516
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	11000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1386312000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1204431000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-248000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-249000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1579500000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1341608000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-193425000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-137418000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	629604000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	480847000
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	257244000
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	211042000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	326551000
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	158992000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	70083000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	57591000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	109436000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	199358000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	363105000
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	192015000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	198481000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	169713000
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	460443000
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	467922000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	590409000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-203199000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-256880000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-263858000
CY2023	us-gaap	Interest Expense InterestExpense	40542000
CY2022	us-gaap	Interest Expense InterestExpense	32474000
CY2021	us-gaap	Interest Expense InterestExpense	22959000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-6222000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5469000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3822000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-283000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-238272000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-291754000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-287100000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-380000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-237892000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-291754000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-287100000
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.53
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.53
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.76
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.76
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.81
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.81
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	94162637
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94162637
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	77630020
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	77630020
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75449632
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75449632
CY2023	us-gaap	Profit Loss ProfitLoss	-237892000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	730000
CY2022	us-gaap	Profit Loss ProfitLoss	-291754000
CY2021	us-gaap	Profit Loss ProfitLoss	-287100000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	22000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-237891000
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-291733000
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-287100000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	280974000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-287100000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10410000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3002000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	40903000
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1753000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	51290000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	97726000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-291754000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	691000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2320000
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3744000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	51188000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	21000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-137418000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-237892000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	694000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1809000
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	58541000
CY2023	chrs	Stock Issued During Period Value Accelerated Vesting Of Equity Awards StockIssuedDuringPeriodValueAcceleratedVestingOfEquityAwards	1053000
CY2023	chrs	Stock Issued During Period Value Taxes Paid Related To Net Share Settlement Of Equity Awards StockIssuedDuringPeriodValueTaxesPaidRelatedToNetShareSettlementOfEquityAwards	347000
CY2023	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3527000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	43540000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-193425000
CY2023	us-gaap	Profit Loss ProfitLoss	-237892000
CY2022	us-gaap	Profit Loss ProfitLoss	-291754000
CY2021	us-gaap	Profit Loss ProfitLoss	-287100000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3791000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3699000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3454000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	43110000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	50737000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	51364000
CY2021	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	-3210000
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	52595000
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	26000000
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	5133000
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	3052000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1095000
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2407000
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	6431000
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4257000
CY2023	chrs	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	2476000
CY2022	chrs	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	2503000
CY2021	chrs	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	2207000
CY2022	chrs	Upfront License Fee Payments Related To License And Collaboration Arrangements UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements	35000000
CY2021	chrs	Upfront License Fee Payments Related To License And Collaboration Arrangements UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements	136000000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-6222000
CY2023	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-1493000
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	25000
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	588000
CY2023	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	150683000
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-13052000
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-34062000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	46734000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	47348000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6253000
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2027000
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	4214000
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-3828000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-16155000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	13424000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5351000
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	23760000
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-4548000
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	874000
CY2023	chrs	Increase Decrease In Accrued Rebates Fees And Reserve IncreaseDecreaseInAccruedRebatesFeesAndReserve	113105000
CY2022	chrs	Increase Decrease In Accrued Rebates Fees And Reserve IncreaseDecreaseInAccruedRebatesFeesAndReserve	-24566000
CY2021	chrs	Increase Decrease In Accrued Rebates Fees And Reserve IncreaseDecreaseInAccruedRebatesFeesAndReserve	-2502000
CY2023	chrs	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	-5373000
CY2022	chrs	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	596000
CY2021	chrs	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	-230000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	10917000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1195000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	17932000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-174884000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-241124000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37432000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	286000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2039000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1289000
CY2023	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	845000
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	19507000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	127382000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	182485000
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	144360000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	99692000
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	13282000
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	81672000
CY2023	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	6997000
CY2022	chrs	Upfront And Milestone Based License Fee Payments Investing Activities UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities	35000000
CY2021	chrs	Upfront And Milestone Based License Fee Payments Investing Activities UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities	136000000
CY2023	chrs	Upfront And Milestone Payments Related To License And Collaboration Arrangements UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements	1051000
CY2022	chrs	Upfront And Milestone Payments Related To License And Collaboration Arrangements UpfrontAndMilestonePaymentsRelatedToLicenseAndCollaborationArrangements	2429000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	144640000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-166850000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-138410000
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	240679000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	694000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	691000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10399000
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1809000
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2320000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3002000
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3587000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3744000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1753000
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	109000000
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	81750000
CY2023	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-1034000
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-1228000
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-672000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	69600000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54326000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	51879000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	39356000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-353648000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-123963000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63987000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	417635000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	541598000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	103343000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63987000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	417635000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	37857000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	34878000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	18684000
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-118000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	40000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1221000
CY2023Q4	chrs	Product Pipeline Number Of Drug Candidates ProductPipelineNumberOfDrugCandidates	3
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Accounting estimates and judgements are inherently uncertain, and the actual results could differ from these estimates.</p>
CY2023	chrs	Number Of Operating And Reportable Segments NumberOfOperatingAndReportableSegments	1
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63547000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	417195000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	541158000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	440000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	440000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	440000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63987000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	417635000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	541598000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102891000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63547000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	417195000
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	452000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	440000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	440000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	103343000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63987000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	417635000
CY2021	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	0
CY2022	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	0
CY2023	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	0
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	2800000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1900000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	1400000
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Risk</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, investments in marketable securities and trade receivables. The Company attempts to minimize the risks related to cash, cash equivalents and marketable securities by investing in a broad and diverse range of financial instruments. The investment portfolio is maintained in accordance with the Company’s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company monitors the credit worthiness of customers that are granted credit in the normal course of business. In general, there is no requirement for collateral from customers.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Substantially all of the Company’s revenues are in the United States to three wholesalers. During 2023, the products sold by the Company were UDENYCA, CIMERLI, YUSIMRY and LOQTORZI. During 2022, UDENYCA and CIMERLI were the only products sold by the Company, and in 2021 UDENYCA accounted for all of the Company’s revenues.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company enters into a strategic commercial supply agreement for each of its products. The Company currently has not engaged back-up suppliers or vendors. If any of the Company’s current vendors are not able to manufacture the supply needed in the quantities and timeframe required, the Company may not be able to supply the product in a timely manner. </p>
CY2023Q4	us-gaap	Derivative Assets DerivativeAssets	0
CY2023	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	0
CY2023	us-gaap	Revenue Performance Obligation Description Of Payment Terms RevenuePerformanceObligationDescriptionOfPaymentTerms	Payment terms differ by jurisdiction and customer, but payment terms typically range from 30 to approximately 90 days from date of shipment and may be extended during the launch period of a new product.
CY2019Q3	chrs	Royalty Payment Term RoyaltyPaymentTerm	P5Y
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	52600000
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	26000000.0
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	5100000
CY2023	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	10900000
CY2022	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	10500000
CY2021	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	8700000
CY2023Q4	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P36M
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	257244000
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	211042000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	326551000
CY2020Q4	chrs	Reserve For Discounts And Allowances Constitute Variable Consideration ReserveForDiscountsAndAllowancesConstituteVariableConsideration	123398000
CY2021	chrs	Reserve For Sales Discounts And Allowances Constitute Variable Consideration ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration	679199000
CY2021	chrs	Provision Related To Sales Made In Prior Period ProvisionRelatedToSalesMadeInPriorPeriod	-11407000
CY2021	chrs	Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration	681467000
CY2021Q4	chrs	Reserve For Discounts And Allowances Constitute Variable Consideration ReserveForDiscountsAndAllowancesConstituteVariableConsideration	109723000
CY2022	chrs	Reserve For Sales Discounts And Allowances Constitute Variable Consideration ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration	578699000
CY2022	chrs	Provision Related To Sales Made In Prior Period ProvisionRelatedToSalesMadeInPriorPeriod	-3108000
CY2022	chrs	Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration	584811000
CY2022Q4	chrs	Reserve For Discounts And Allowances Constitute Variable Consideration ReserveForDiscountsAndAllowancesConstituteVariableConsideration	100503000
CY2023	chrs	Reserve For Sales Discounts And Allowances Constitute Variable Consideration ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration	844325000
CY2023	chrs	Provision Related To Sales Made In Prior Period ProvisionRelatedToSalesMadeInPriorPeriod	3807000
CY2023	chrs	Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration	703750000
CY2023Q4	chrs	Reserve For Discounts And Allowances Constitute Variable Consideration ReserveForDiscountsAndAllowancesConstituteVariableConsideration	244885000
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-900000
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	191645000
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	104324000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	11000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	104315000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	191623000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	43000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	21000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	191645000
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	9
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	13
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2023	chrs	Contractual Maturities Of Available For Sale Debt Securities Remaining Maturity ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity	P1Y
CY2023	chrs	Remaining Contractual Maturities Of Available For Sale Debt Securities Acquisition RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition	P9M
CY2022	chrs	Remaining Contractual Maturities Of Available For Sale Debt Securities Acquisition RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition	P7M
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	12975000
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	10262000
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	82588000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	86712000
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	34537000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	18077000
CY2023Q4	us-gaap	Inventory Gross InventoryGross	130100000
CY2022Q4	us-gaap	Inventory Gross InventoryGross	115051000
CY2023Q4	us-gaap	Inventory Net InventoryNet	62605000
CY2022Q4	us-gaap	Inventory Net InventoryNet	38791000
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	67495000
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	76260000
CY2023Q4	chrs	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	130100000
CY2022Q4	chrs	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	115051000
CY2023Q4	chrs	Prepaid Manufacturing Expense Current PrepaidManufacturingExpenseCurrent	23700000
CY2023Q4	chrs	Prepayments Made To Cmo For Manufacturing Services PrepaymentsMadeToCmoForManufacturingServices	12600000
CY2023Q4	chrs	Prepayments Made To Cmo For Other Research And Development Pipeline Program PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram	11100000
CY2022Q4	chrs	Prepaid Manufacturing Expense Current PrepaidManufacturingExpenseCurrent	17900000
CY2022Q4	chrs	Prepayments Made To Cmo For Manufacturing Services PrepaymentsMadeToCmoForManufacturingServices	13000000.0
CY2022Q4	chrs	Prepayments Made To Cmo For Other Research And Development Pipeline Program PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram	4900000
CY2021	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	0
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	25770000
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	28911000
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	20651000
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	20157000
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	5119000
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	8754000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3200000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3600000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3500000
CY2021	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0
CY2022	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0
CY2023	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0
CY2023Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	3200000
CY2022Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	3500000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	639000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	61000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	41871000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2368000
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	28859000
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	2620000
CY2023Q4	us-gaap	Goodwill Goodwill	943000
CY2022Q4	us-gaap	Goodwill Goodwill	943000
CY2023Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	71673000
CY2022Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	5931000
CY2023	chrs	Finite Lived Intangible Asset Expected Amortization For Each Of Five Succeeding Fiscal Years FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears	3800000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P11Y4M24D
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0
CY2023	chrs	Upfront And Milestone Payment UpfrontAndMilestonePayment	25000000.0
CY2023Q4	chrs	Accrued Commercial And Research And Development Manufacturing Liabilities Current AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent	23470000
CY2022Q4	chrs	Accrued Commercial And Research And Development Manufacturing Liabilities Current AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent	21774000
CY2023Q4	chrs	Accrued Co Development Costs And Milestone Payments AccruedCoDevelopmentCostsAndMilestonePayments	26812000
CY2022Q4	chrs	Accrued Co Development Costs And Milestone Payments AccruedCoDevelopmentCostsAndMilestonePayments	8356000
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	42031000
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	5015000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7628000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10634000
CY2023Q4	chrs	Lease Liabilities Operating And Financing LeaseLiabilitiesOperatingAndFinancing	2145000
CY2022Q4	chrs	Lease Liabilities Operating And Financing LeaseLiabilitiesOperatingAndFinancing	4318000
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	3300000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	105386000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	50097000
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1172000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	102000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1102000
CY2023Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	10287000
CY2022Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	3365000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12561000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3467000
CY2023Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	38400000
CY2022Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	2900000
CY2020Q2	us-gaap	Share Price SharePrice	14.82
CY2020Q2	us-gaap	Share Price SharePrice	14.82
CY2023Q4	us-gaap	Share Price SharePrice	3.33
CY2023Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	52514000
CY2023Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	19154000
CY2023Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	1410000
CY2023Q4	us-gaap	Purchase Obligation PurchaseObligation	73078000
CY2022Q2	us-gaap	Product Liability Contingency Loss Exposure Not Accrued Best Estimate ProductLiabilityContingencyLossExposureNotAccruedBestEstimate	14000000.0
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5912000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5690000
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1022000
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	2584000
CY2023Q4	chrs	Operating And Finance Lease Right Of Use Assets OperatingAndFinanceLeaseRightOfUseAssets	6934000
CY2022Q4	chrs	Operating And Finance Lease Right Of Use Assets OperatingAndFinanceLeaseRightOfUseAssets	8274000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1424000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3127000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4977000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3628000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6401000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6755000
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	721000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1191000
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	351000
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1418000
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1072000
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	2609000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y7M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y2M12D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y4M24D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M12D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.118
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.087
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.084
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.058
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1069000
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1228000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	707000
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	146000
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	166000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	82000
CY2023	chrs	Finance Lease Cost FinanceLeaseCost	1215000
CY2022	chrs	Finance Lease Cost FinanceLeaseCost	1394000
CY2021	chrs	Finance Lease Cost FinanceLeaseCost	789000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	2984000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	3154000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	3066000
CY2023	us-gaap	Lease Cost LeaseCost	4199000
CY2022	us-gaap	Lease Cost LeaseCost	4548000
CY2021	us-gaap	Lease Cost LeaseCost	3855000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	3560000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	3401000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	3435000
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	145000
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	155000
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	81000
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1034000
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1228000
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	672000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2653000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	434000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	2694000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	477000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2095000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	781000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2192000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	358000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2126000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1531000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7944000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	1139000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1543000
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	67000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6401000
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1072000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	37400000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	43110000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	50737000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	51364000
CY2023	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1062000
CY2022	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1187000
CY2021	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	1025000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-238272000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-291746000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-287058000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-8000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-42000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-238272000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-291754000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-287100000
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-380000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-380000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-380000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.012
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.017
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.026
CY2022	chrs	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.001
CY2021	chrs	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.002
CY2023	chrs	Effective Income Tax Rate Reconciliation Tax Expense And Credits Research EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch	0.009
CY2022	chrs	Effective Income Tax Rate Reconciliation Tax Expense And Credits Research EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch	0.018
CY2021	chrs	Effective Income Tax Rate Reconciliation Tax Expense And Credits Research EffectiveIncomeTaxRateReconciliationTaxExpenseAndCreditsResearch	0.026
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.035
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.023
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.012
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.007
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.177
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.221
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.252
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.002
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	170402000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	131423000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	65225000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	63164000
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	37211000
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	51877000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	30370000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	32561000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	38474000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	23864000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	42480000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	19717000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	46062000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	17673000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	430224000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	340279000
CY2023Q4	chrs	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	1538000
CY2022Q4	chrs	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	1903000
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	6403000
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	603000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	7941000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2506000
CY2023Q4	chrs	Deferred Tax Asset Liability Net DeferredTaxAssetLiabilityNet	422283000
CY2022Q4	chrs	Deferred Tax Asset Liability Net DeferredTaxAssetLiabilityNet	337773000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	423385000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	337773000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1102000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	85600000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	64400000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	72400000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	16838000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	15495000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13243000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	865000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1385000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2038000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	286000
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	42000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	214000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	17417000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	16838000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	15495000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	17400000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	16800000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	15500000
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	38291761
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	37635124
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	38122727
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	800000

Files In Submission

Name	View Source	Status
0001558370-24-003436-index-headers.html	Edgar Link	pending
0001558370-24-003436-index.html	Edgar Link	pending
0001558370-24-003436.txt	Edgar Link	pending
0001558370-24-003436-xbrl.zip	Edgar Link	pending
chrs-20231231.xsd	Edgar Link	pending
chrs-20231231x10k.htm	Edgar Link	pending
chrs-20231231x10k007.jpg	Edgar Link	pending
chrs-20231231xex1.htm	Edgar Link	pending
chrs-20231231xex10.htm	Edgar Link	pending
chrs-20231231xex1002.jpg	Edgar Link	pending
chrs-20231231xex10d40.htm	Edgar Link	pending
chrs-20231231xex2.htm	Edgar Link	pending
chrs-20231231xex21d1.htm	Edgar Link	pending
chrs-20231231xex23.htm	Edgar Link	pending
chrs-20231231xex3.htm	Edgar Link	pending
chrs-20231231xex31.htm	Edgar Link	pending
chrs-20231231xex32.htm	Edgar Link	pending
chrs-20231231xex33.htm	Edgar Link	pending
chrs-20231231xex4.htm	Edgar Link	pending
chrs-20231231xex5.htm	Edgar Link	pending
chrs-20231231xex7.htm	Edgar Link	pending
chrs-20231231xex8.htm	Edgar Link	pending
chrs-20231231xex9.htm	Edgar Link	pending
chrs-20231231xex9001.jpg	Edgar Link	pending
chrs-20231231xex9002.jpg	Edgar Link	pending
chrs-20231231xex97.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
chrs-20231231_cal.xml	Edgar Link	unprocessable
chrs-20231231_lab.xml	Edgar Link	unprocessable
chrs-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
chrs-20231231x10k_htm.xml	Edgar Link	completed
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
chrs-20231231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CHRS
Coherus BioSciences Inc Stock $chrs

2024 Q1 Form 10-K Financial Statement

#000155837024003436 Filed on March 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHRS Coherus BioSciences Inc Stock $chrs

2024 Q1 Form 10-K Financial Statement

#000155837024003436 Filed on March 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHRS
Coherus BioSciences Inc Stock $chrs